Regulatory guidance for pharmaceutical companies to prepare for UK’s withdrawal from EU
EMA and European Commission publish updated Q&As
The European Medicines Agency (EMA) and the European Commission have published additional guidance to help pharmaceutical companies prepare for the United Kingdom’s withdrawal from the European Union (EU).
Companies are reminded to plan in advance for the situation that the United Kingdom (UK) will leave the EU on 29 March 2019 in order to avoid any impact on the continuous supply of medicines for human and veterinary use within the EU.
This version is an update of the initial questions-and-answers document that was published at the end of May 2017. Updates are marked ‘NEW’ and include additional information on how the UK’s withdrawal from the EU will affect marketing applications and authorisations for different types of medicinal products, for example, generic, hybrid and biosimilar medicines.
The guidance relates to both human and veterinary medicines, unless otherwise indicated.
Earlier this week, the Agency published the first version of its procedural guidance for industry which outlines the practical and simplified requirements that companies should follow to make sure that necessary changes to their marketing authorisation are made by the end of March 2019, to allow for the continued marketing of their medicine in the European Economic Area (EEA) after Brexit.
Companies are advised to regularly check EMA’s dedicated webpage on the consequences of the UK’s withdrawal from the EU.
This questions-and-answers document follows the publication of the European Commission/EMA notice to marketing authorisation holders of centrally authorised medicines for human and veterinary use on 2 May 2017.
Questions and answers related to the United Kingdom's withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the centralised procedure (01/12/2017)
Latest News from
ESMA consults on potential CFD and binary options measures to protect retail investors18/01/2018 16:25:00
The European Securities and Markets Authority (ESMA) has published a call for evidence on potential product intervention measures relating to the provision of contracts for differences (CFDs), including rolling spot forex, and binary options to retail investors.
New measures to boost key competences & digital skills, as well as the European dimension of education18/01/2018 15:43:00
To follow up on the Gothenburg Summit, the European Commission yesterday adopted new initiatives to improve key competences and digital skills of European citizens, to promote common values and pupils' awareness of the functioning of the European Union.
Education and training initiatives18/01/2018 15:10:00
To follow up on the Gothenburg Summit, the EC has adopted new initiatives to improve key competences & digital skills of European citizens, to promote common values and pupils' awareness of the functioning of the European Union.
Effort sharing regulation: EU ambassadors approve provisional agreement18/01/2018 14:25:00
EU ambassadors gave given their support to the provisional agreement reached between the Estonian presidency and the European Parliament in December 2017 on the effort sharing regulation.
IP Key China official launch18/01/2018 13:47:00
On 17 January the Office officially launched the new IP Key China in Beijing, during an event attended by Christian Archambeau,On 17 January the Office officially launched the new IP Key China in Beijing, during an event attended by Christian Archambeau.